This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Stella Maris trials | |
|---|---|
| Name | Stella Maris trials |
| Type | Clinical trial series |
| Phase | Mixed-phase |
| Start | 20XX |
| Completed | 20XX |
| Principal investigator | Dr. Jane Doe |
| Sponsor | Aurora Biomedical Institute |
| Locations | Port-au-Prince, Marseille, Boston |
| Interventions | Investigational agent SMX-101 |
| Conditions | Refractory serosal infections |
Stella Maris trials were a multi-center clinical development program evaluating the investigational agent SMX-101 for refractory serosal infections and associated inflammatory syndromes. The program combined randomized controlled studies, open-label extensions, and adaptive platform components across sites in the Caribbean, Europe, and North America. Trials engaged multiple academic centers, biotechnology sponsors, and regulatory authorities to assess efficacy, safety, biomarker responses, and health-economic endpoints.
The Stella Maris program arose from preclinical work at the Aurora Biomedical Institute and translational collaborations with the Institut Pasteur and the Broad Institute. Early mechanistic studies referenced signaling pathways identified in mouse models from the Sanger Institute and target validation publications from Harvard Medical School investigators. Funding and strategic partnerships involved the Wellcome Trust, the Bill & Melinda Gates Foundation, and the private firm Maris Therapeutics. The development plan was informed by prior clinical experiences with agents tested in the RECOVERY trial, the SOLIDARITY trial, and the CANTOS trial, and by regulatory guidance from the European Medicines Agency and the U.S. Food and Drug Administration. Site selection considered epidemiology from reports by the World Health Organization and cohort registries maintained by the Centers for Disease Control and Prevention.
Stella Maris trials comprised a randomized, double-blind, placebo-controlled pivotal study, an adaptive dose-finding phase, and open-label extension cohorts. Randomization strata mirrored design elements used in the Randomized Aldactone Evaluation Study and incorporated adaptive Bayesian features similar to the I-SPY 2 trial. Primary endpoints paralleled measures used in the SOLVE trial and included clinical resolution rates and biomarker reduction measured against historical controls from the Framingham Heart Study and sepsis cohorts cataloged by the International Sepsis Forum. Eligibility criteria referenced diagnostic algorithms developed at the Mayo Clinic and case definitions from the European Centre for Disease Prevention and Control. Centralized laboratories at the University of Oxford and the Johns Hopkins University performed pharmacokinetic and pharmacodynamic assays, while imaging assessments adhered to standards from the Radiological Society of North America.
Primary analyses reported that SMX-101 met the predefined efficacy boundary for clinical resolution at day 28 in the intention-to-treat population, with effect sizes compared to placebo reflecting methodologies used in the DAPA-HF trial and the EMPA-REG OUTCOME trial. Secondary outcomes included reductions in inflammatory biomarkers observed in assays validated by the National Institutes of Health and improved functional scores consistent with metrics from the Kardashian Functional Index—a composite adapted from instruments at the Massachusetts General Hospital and the Cleveland Clinic. Subgroup analyses evaluated outcomes across cohorts recruited from centers including Hôpital de la Positif and the Mount Sinai Health System, and results were stratified by baseline characteristics aligning with datasets from the UK Biobank and the Framingham Heart Study. Adaptive interim analyses triggered modifications reminiscent of decisions made in the RECOVERY trial platform.
Safety monitoring employed independent data monitoring committees drawn from experts affiliated with the European Medicines Agency, the U.S. Food and Drug Administration, and academic centers such as Columbia University and Stanford University School of Medicine. Adverse event reporting used standardized terms from the Council for International Organizations of Medical Sciences and severity grading aligned with the Common Terminology Criteria for Adverse Events. Observed serious adverse events included hepatotoxicity signals, infusion reactions, and rare thromboembolic events; these were adjudicated by committees modeled after panels used in the CAST trial and the SOLID trial. Risk mitigation incorporated pharmacovigilance practices from the Pharmacovigilance Risk Assessment Committee and dosing algorithms developed in conjunction with the European Society of Cardiology and the American Society of Hematology.
Regulatory submissions paralleled dossiers prepared for the European Medicines Agency and the U.S. Food and Drug Administration, and engaged expedited pathways analogous to those used by sponsors in the Breakthrough Therapy designation program. Ethical oversight involved institutional review boards at participating centers including Université de Montréal and Boston University School of Medicine, and compliance with international standards such as the Declaration of Helsinki and the International Council for Harmonisation guidelines. Community engagement and informed consent procedures referenced models developed by the World Health Organization and ethics frameworks employed in the HVTN network and the Malaria Vaccine Implementation Programme.
Following publication, data from Stella Maris stimulated follow-on studies at institutions such as Imperial College London, Yale School of Medicine, and the Karolinska Institutet. Meta-analyses incorporating Stella Maris data were undertaken by consortia including the Cochrane Collaboration and the Global Health Network. Industry partnerships led to a phase III expansion trial coordinated with GlaxoSmithKline and academic translational efforts funded by the National Institutes of Health and the Wellcome Trust. Biomarker substudies informed mechanistic projects at the Salk Institute and the Max Planck Society, and health-policy assessments referenced frameworks from the Organisation for Economic Co-operation and Development and the World Bank.
Category:Clinical trials